Cell therapies represent an important advancement in our ability to treat difficult cancers, but continued exploration of this new modality will require new digital tools and equipment.
- PUPSIT In Cell & Gene Therapy: Risk Reduction Or Operational Complexity?
- Is Your AI Model Trustworthy And Credible In GMP Processes?
- May 2026 — CDMO Opportunities And Threats Report
- In Vivo Gene Editing Is Moving From Promise To Proof
- Why Improving Drug Delivery Remains A Major Opportunity In Oncology
- FDA's Guidance On Cell And Gene CMC Codifies Flexibility
- Strategic Synthesis Of ASGCT And ASCO 2026
- Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![dna, rna molecules-GettyImages-537327406]( "Optimize DNA Clearance In High-Salt, GMP-Grade Purification Processes")
Optimize DNA Clearance In High-Salt, GMP-Grade Purification ProcessesEfficient hcDNA removal is vital for therapeutic safety and compliance. Discover how salt-active enzymes support high-salt purification workflows to help manufacturers meet strict regulatory standards.
-
![GettyImages- 2146163342 ISO standards]( "ISO 21973: How To Ensure Full Compliance Throughout Every Step Of The Journey")
ISO 21973: How To Ensure Full Compliance Throughout Every Step Of The JourneyLearn how ISO 21973, a vital standard for ensuring safe and reliable transport of cell and gene therapies, enhances supply chain efficiency and mitigates risks for the regenerative medicine industry.
-
![tablet for medicine management, stock research or inventory, Digital technology-GettyImages-1666055403]( "Reducing Inventory Errors In Clinical Trials")
Reducing Inventory Errors In Clinical TrialsCan a digital double-check save your trial from data errors? How does verifying shipments at receipt slash inventory mistakes? Learn to protect protocol integrity and patient safety.
-
![GettyImages-2036497889-lab-computer-research]( "Transforming Clinical Trial Management")
Transforming Clinical Trial ManagementSee how Vestigo® can transform your study management — streamline workflows, strengthen compliance, and eliminate inefficiencies by adopting a smarter, digital-first approach today.
-
![GettyImages-1634050535 data, logistics]( "Expert Insights In Navigating CGT's Complex Supply Chain")
Expert Insights In Navigating CGT's Complex Supply ChainExamine insights shared during Cencora's ThinkLive Cell and Gene Therapy Summit 2024 that shed light on the challenges and opportunities in navigating the complexities of the cell and gene supply chain.
-
![Cencora - Payer Coverage white paper]( "Evolving Landscape Of Payer Coverage For CGTs: Trends And Insights")
Evolving Landscape Of Payer Coverage For CGTs: Trends And InsightsExamine how proactive payer engagement and robust clinical evidence regarding comparative effectiveness and durability of response can overcome significant reimbursement barriers and enhance patient access.
-
![GettyImages-1220382102-lab-research]( "A Scalable Platform To Revolutionize Gene Therapy Manufacturing")
A Scalable Platform To Revolutionize Gene Therapy ManufacturingDiscover how our innovative rAAV production platform can revolutionize your gene therapy pipeline with unparalleled yield, quality, and scalability.
-
![GettyImages-1269813787 mobile visit nurse]( "Enhance Access And Improve Retention In Rare Disease Trials With HTS")
Enhance Access And Improve Retention In Rare Disease Trials With HTSHome Trial Support (HTS) provides a solution to improving participant recruitment and retention during musculoskeletal studies.
-
![GettyImages-627023398 clinical lab]( "AAV Viral Titering Using Nanoplate-Based Digital PCR")
AAV Viral Titering Using Nanoplate-Based Digital PCRExamine how nanoplate-based digital PCR streamlines AAV titering, providing faster results and greater accuracy, advancing gene therapy development from the lab to the clinic.
-
![GettyImages-1382353763-computer-medical-documents-review]( "Building A High-Quality IND From Scratch With Strategic Gap Analysis")
Building A High-Quality IND From Scratch With Strategic Gap AnalysisA biotech sponsor lacking in-house regulatory expertise engaged a partner to obtain strategic regulatory review, medical writing, project management, and electronic publishing (eCTD).
NEWSLETTER ARCHIVE
- 06.26.26 -- Reimagining In Vivo Gene Editing Through Base Editing And Targeted Delivery
- 06.25.26 -- Fixing The Fragmentation In Outsourced Pharma
- 06.25.26 -- Better Biopharma's Editors' Roundtable — A Midyear Look At The 2026 Life Sciences Industry
- 06.24.26 -- Smarter risk management for single-use and filtration systems.
- 06.24.26 -- What's Driving Cell & Gene Therapy Forward? Key Trends & Insights
- In Vivo Gene Editing Is Moving From Promise To Proof
- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections
